These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20089418)

  • 1. Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing process conditions.
    Roberts PL; Feldman P; Crombie D; Walker C; Lowery K
    Biologicals; 2010 Mar; 38(2):303-10. PubMed ID: 20089418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Removal of virus through novel membrane filtration method.
    Manabe S
    Dev Biol Stand; 1996; 88():81-90. PubMed ID: 9119166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
    Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
    Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
    Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
    J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
    Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
    Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removal of small non-enveloped viruses by nanofiltration.
    Yokoyama T; Murai K; Murozuka T; Wakisaka A; Tanifuji M; Fujii N; Tomono T
    Vox Sang; 2004 May; 86(4):225-9. PubMed ID: 15144526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography.
    Roberts PL; Walker CP; Feldman PA
    Vox Sang; 1994; 67 Suppl 1():69-71. PubMed ID: 8091741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
    Troccoli NM; McIver J; Losikoff A; Poiley J
    Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-round virus filter integrity test sensitivity.
    Dowd CJ
    Biotechnol Bioeng; 2009 Jun; 103(3):574-81. PubMed ID: 19253932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scrapie removal using Planova virus removal filters.
    Tateishi J; Kitamoto T; Mohri S; Satoh S; Sato T; Shepherd A; Macnaughton MR
    Biologicals; 2001 Mar; 29(1):17-25. PubMed ID: 11482889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus elimination during the recycling of chromatographic columns used during the manufacture of coagulation factors.
    Roberts PL
    Biologicals; 2014 Jul; 42(4):184-90. PubMed ID: 24981392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
    Roberts PL; Dunkerley C; McAuley A; Winkelman L
    Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
    Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
    Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The removal of viruses during the purification of equine antisera using filtration aids Hyflo Super-Cel and Fulmon Super A.
    Cameron-Smith R; Miloradovic L; Cheyne I; Healy K
    Biologicals; 2000 Sep; 28(3):169-74. PubMed ID: 10964443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII.
    Roberts PL
    Biologicals; 2008 Sep; 36(5):330-5. PubMed ID: 18674928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
    Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
    Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antibody solution conditions on filter performance for virus removal filter Planova 20N.
    Hongo-Hirasaki T; Komuro M; Ide S
    Biotechnol Prog; 2010; 26(4):1080-7. PubMed ID: 20730765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective poxvirus removal by sterile filtration during manufacture of plasma derivatives.
    Berting A; Goerner W; Spruth M; Kistner O; Kreil TR
    J Med Virol; 2005 Apr; 75(4):603-7. PubMed ID: 15714487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of a microporous polyvinylidene fluoride (PVDF) membrane filter to separate contaminating viral particles from biologically important proteins.
    Oshima KH; Evans-Strickfaden TT; Highsmith AK; Ades EW
    Biologicals; 1996 Jun; 24(2):137-45. PubMed ID: 8889061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.